Sugi Predict

Sugi Predict / Compounds / SCHEMBL364570

SCHEMBL364570

SCHEMBL364570

COC(=O)Cc1cccc(Cl)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.47
▸ HPGD P15428 2/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ TP53 P04637 1/20 0.47
▸ POLB P06746 1/20 0.47
▸ ALDH1A1 P00352 8/20 0.46
▸ GAA P10253 3/20 0.44
▸ MAPT P10636 3/20 0.44
▸ AGTR1 P30556 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ GRM5 P41594 1/20 0.39
▸ CYP4F2 P78329 1/20 0.39
▸ CYP4A11 Q02928 1/20 0.39
▸ CYP1A2 P05177 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31638154 0.83 MAPT (0.47) SMN1; SMN2NPC1RAB9ATP53MAPT
SCHEMBL1646319 0.83 MAPT (0.47) SMN1; SMN2NPC1RAB9ATP53MAPT
SCHEMBL21906534 0.83 SMN1; SMN2 (0.44) SMN1; SMN2HPGDNPC1RAB9ATP53
Hydrochloric Acid SCHEMBL20975356 0.81 KDM4E (0.43) SMN1; SMN2HPGDNPC1RAB9ATP53
SCHEMBL10381880 0.81 MEN1 (0.52) SMN1; SMN2HPGDNPC1RAB9ATP53
SCHEMBL15752593 0.81 NPSR1 (0.44) SMN1; SMN2HPGDNPC1RAB9ATP53
SCHEMBL3184758 0.80 ALDH1A1 (0.46) SMN1; SMN2HPGDNPC1RAB9AALDH1A1
SCHEMBL15709960 0.79 ALDH1A1 (0.41) SMN1; SMN2HPGDNPC1RAB9ATP53
SCHEMBL15709754 0.79 PSMB5 (0.44) SMN1; SMN2HPGDNPC1RAB9ATP53
SCHEMBL3924027 0.79 ALDH1A1 (0.41) SMN1; SMN2HPGDNPC1RAB9ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9765029-B2 Pyridine compounds as sodium channel blockers PURDUE PHARMA L.P. (US) 2017-09-19 — — US disclosed
US-9765029-B2 Pyridine compounds as sodium channel blockers PURDUE PHARMA L.P. (US) 2017-09-19 — — US disclosed
US-9765029-B2 Pyridine compounds as sodium channel blockers PURDUE PHARMA L.P. (US) 2017-09-19 — — US disclosed
EP-2822931-B1 TRIAZOLONE COMPOUNDS AND USES THEREOF INCEPTION 2 INC (US) 2017-05-03 — — EP disclosed
US-9505728-B2 Triazolone compounds and uses thereof INCEPTION 2, INC. (US) 2016-11-29 — — US disclosed
US-20150344465-A1 PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS PURDUE PHARMA L.P. 2015-12-03 — — US disclosed
US-20150344465-A1 PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS PURDUE PHARMA L.P. 2015-12-03 — — US disclosed
US-20150344465-A1 PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS PURDUE PHARMA L.P. 2015-12-03 — — US disclosed
US-9120752-B2 Pyridine compounds as sodium channel blockers PURDUE PHARMA, L.P. (US) 2015-09-01 — — US disclosed
US-9120752-B2 Pyridine compounds as sodium channel blockers PURDUE PHARMA, L.P. (US) 2015-09-01 — — US disclosed
WO-2012007836-A1 PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS PURDUE PHARMA .LP. (US) 2012-01-19 — — WO disclosed
US-7776897-B2 such as 3-[1-(5-chloro-2-thienyl)cyclopenty]-5,6,7,8,9,10-hexahydro [1,2,4]triazolo[4,3-a]azocine, having a strong 11 beta -hydroxysteroid dehydrogenase type 1inhibitory activity and exhibiting an excellent blood-glucose level-lowering action, used for the therapy of diabetes and insulin resistance ASTELLAS PHARMA INC. (JP) 2010-08-17 — — US disclosed
US-7776897-B2 such as 3-[1-(5-chloro-2-thienyl)cyclopenty]-5,6,7,8,9,10-hexahydro [1,2,4]triazolo[4,3-a]azocine, having a strong 11 beta -hydroxysteroid dehydrogenase type 1inhibitory activity and exhibiting an excellent blood-glucose level-lowering action, used for the therapy of diabetes and insulin resistance ASTELLAS PHARMA INC. (JP) 2010-08-17 — — US disclosed
CN-101400660-A Triazole derivative or salt thereof ASTELLAS PHARMA INC (JP) 2009-04-01 — — CN disclosed
US-20090082367-A1 TRIAZOLE DERIVATIVE OR A SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-03-26 — — US disclosed
US-20090082367-A1 TRIAZOLE DERIVATIVE OR A SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-03-26 — — US disclosed
EP-1995243-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2008-11-26 — — EP disclosed
US-20070259854-A1 Triazole Derivative or Salt Thereof ASTELLAS PHARMA INC. (JP) 2007-11-08 — — US disclosed
US-20070259854-A1 Triazole Derivative or Salt Thereof ASTELLAS PHARMA INC. (JP) 2007-11-08 — — US disclosed
EP-1790641-A1 TRIAZOLE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2007-05-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259854-A1 Triazole Derivative or Salt Thereof HSD11B1, HSD11B2, HSD3B1 SMN1; SMN2 3427/4885HPGD 233/4885NPC1 566/4885
US-20090082367-A1 TRIAZOLE DERIVATIVE OR A SALT THEREOF HSD11B1, HSD11B2, HSD17B1 SMN1; SMN2 3838/4885HPGD 241/4885NPC1 619/4885
US-20150344465-A1 PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS SCN1B, CACNA1A, SCN1A SMN1; SMN2 429/4885HPGD 1119/4885NPC1 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.